Table 2.
Baseline variables identified by Pocock with trends across the Kansas City Cardiomyopathy Questionnaire’s (KCCQ)
| All patients n = 143 | KCCQ overall summary score categories | |||||
|---|---|---|---|---|---|---|
| Worst (<25) n = 32 |
Poor (25–49) n = 45 |
Fair (50–74) n = 39 |
Good (75–100) n = 27 |
Trend test p value | ||
| Age—years | 68 ± 12 | 67 ± 13 | 71 ± 12 | 67 ± 13 | 67 ± 11 | 0.57 |
| Left ventricular ejection fraction (%) | 28 ± 7 | 28 ± 7 | 27 ± 6 | 27 ± 8 | 29 ± 8 | 0.40 |
| NYHA class III–IV—no (%) | 83 (58.0) | 24 (75.0) | 35 (77.8) | 18 (46.2) | 6 (22.2) | <0.001 |
| Creatininea (mg/dl) | 1.44 (1.45) | 1.30 (1.44) | 1.50 (1.4) | 1.45 (1.44) | 1.30 (1.44) | 0.49 |
| Diabetes—no (%) | 46 (32.2) | 11 (34.4) | 9 (20.0) | 17 (43.6) | 9 (33.3) | 0.45 |
| Beta-blocker—no (%) | 114 (79.7) | 30 (93.8) | 34 (75.6) | 29 (74.4) | 21 (77.8) | 0.13 |
| Systolic blood pressure (mmHg) | 113 ± 26 | 116 ± 20 | 115 ± 23 | 110 ± 32 | 107 ± 27 | 0.12 |
| Body mass index (kg/m2) | 27.0 ± 4.8 | 28.4 ± 5.9 | 26.2 ± 5.4 | 26.7 ± 4.3 | 27.0 ± 3.4 | 0.92 |
| Time since diagnosis (months) | 38 ± 44 | 41 ± 45 | 41 ± 37 | 44 ± 55 | 23 ± 35 | 0.09 |
| Smoker within past 12 months—no (%) | 36 (25.2) | 11 (34.4) | 9 (20.0) | 7 (17.9) | 9 (33.3) | 0.80 |
| COPD—no (%) | 22 (15.4) | 9 (28.1) | 8 (17.8) | 4 (10.3) | 1 (3.7) | 0.008 |
| Male—no (%) | 106 (74.1) | 23 (71.9) | 32 (71.1) | 28 (71.8) | 23 (85.2) | 0.29 |
| ACEor Sartan—no (%) | 135 (94.4) | 27 (84.4) | 44 (97.8) | 38 (97.4) | 26 (96.3) | 0.07 |
| Pocock’s clinical score | 34 ± 15 | 38 ± 16 | 36 ± 14 | 34 ± 16 | 31 ± 14 | 0.04 |
Plus minus data are mean ± SD
COPD chronic obstructive pulmonary disease, ACE angiotensin-converting-enzyme inhibitor
aData are geometric means (SD)